11/20
07:07 am
cstl
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
11/20
07:00 am
cstl
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
11/19
07:15 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year [Yahoo! Finance]
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year [Yahoo! Finance]
11/19
07:00 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
11/12
06:17 am
cstl
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest [Yahoo! Finance]
Low
Report
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest [Yahoo! Finance]
11/8
10:59 am
cstl
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
11/8
07:00 am
cstl
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Low
Report
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
11/7
07:00 am
cstl
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
Low
Report
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
11/6
11:05 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Scotiabank from $37.00 to $44.00. They now have a "sector outperform" rating on the stock.
Low
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Scotiabank from $37.00 to $44.00. They now have a "sector outperform" rating on the stock.
11/6
07:00 am
cstl
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
Medium
Report
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
11/6
06:58 am
cstl
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/5
06:43 pm
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Lake Street Capital from $34.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Lake Street Capital from $34.00 to $40.00. They now have a "buy" rating on the stock.
11/5
02:14 pm
cstl
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/5
08:17 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $39.00. They now have an "outperform" rating on the stock.
High
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $39.00. They now have an "outperform" rating on the stock.
11/5
08:17 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at KeyCorp from $28.00 to $36.00. They now have an "overweight" rating on the stock.
High
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at KeyCorp from $28.00 to $36.00. They now have an "overweight" rating on the stock.
11/4
04:45 pm
cstl
Castle Biosciences Reports Third Quarter 2024 Results [Yahoo! Finance]
High
Report
Castle Biosciences Reports Third Quarter 2024 Results [Yahoo! Finance]
11/4
04:05 pm
cstl
Castle Biosciences Reports Third Quarter 2024 Results
Medium
Report
Castle Biosciences Reports Third Quarter 2024 Results
10/29
04:30 pm
cstl
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
Low
Report
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
10/29
09:17 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $35.00 to $42.00. They now have a "buy" rating on the stock.
Medium
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $35.00 to $42.00. They now have a "buy" rating on the stock.
10/28
07:00 am
cstl
Castle Biosciences to Participate in Upcoming Investor Conferences
Medium
Report
Castle Biosciences to Participate in Upcoming Investor Conferences
10/23
10:16 am
cstl
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going [Yahoo! Finance]
Low
Report
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going [Yahoo! Finance]
10/22
01:57 pm
cstl
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
Low
Report
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
10/20
05:00 am
cstl
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
Low
Report
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
10/16
07:00 am
cstl
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
Low
Report
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
10/15
10:48 am
cstl
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]
Low
Report
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]